In a pilot phase II clinical trial, our group demonstrated that the Notch1 mRNA upregulation post valproic acid treatment, a known HDAC inhibitor, was associated with improved outcomes in patients with carcinoid tumors [25]. The gene discussed is NOTCH1; the disease is carcinoid tumor.